Pharma

Pharmalot

Pharmalittle: Generic shortages loom as coronavirus worsens; Connecticut lawmakers look to cap insulin costs

By Ed Silverman

Pharmalot

Americans with employer coverage saw growth in drug spending outpace other medical costs

By Ed Silverman

Pharmalot

As opioid crisis intensified, many family doctors found promotional pitches were very good

By Ed Silverman

Pharmalot

Pharmalittle: India struggles with coronavirus; CVS and Sanofi shake up management

By Ed Silverman

Pharmalot

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

By Ed Silverman

Pharmalot

Pharmalittle: Big pharma isn’t stepping up to make a coronavirus vaccine; Chinese drug maker threatens Gilead patent

By Ed Silverman

Pharmalot

After a new version of a decades-old drug gets orphan status, the price suddenly skyrockets

By Ed Silverman

Pharmalot

WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’

By Ed Silverman

Pharmalot

Pharmalittle: Trump considers executive action to cut drug prices; feds ‘not done’ with generic price-fixing probe

By Ed Silverman

Pharmalot

Pharmalittle: Two more Alzheimer’s drugs fail in studies; how Democratic candidates differ on lowering drug costs

By Ed Silverman

Pharmalot

California scolds McKesson for supplying excessive controlled substances to a children’s pharmacy

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Novartis lottery for gene therapy begins amid tough questions; coronavirus vaccine may take a year

By Ed Silverman

Pharmalot

U.S. officials lash out at the Dutch government for moves that ‘undermine’ pharma patent rights

By Ed Silverman

Pharmalot

Pharmalittle: Buttigieg wants pharma to ‘thrive’; U.S. patent panel boosts Biogen, disappoints Gilead

By Ed Silverman

Pharmalot

Years later, raw clinical trial data tells us the extent of Avandia’s heart risks

By Ed Silverman

Pharmalot

Gilead loses its challenge to a pair of U.S. patents for an HIV prevention pill

By Ed Silverman

Pharmalot

Pharmalittle: Trump claims on drug prices are mostly false; Merck to spin off old drugs into new company

By Ed Silverman

Pharmalot

A former Taro Pharma executive is indicted in generic price-fixing probe

By Ed Silverman

Pharmalot

Pharma execs argue new Canadian regulations for setting drug prices will hurt the country

By Ed Silverman

Pharmalot

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

By Ed Silverman

Pharmalot

Pharmalittle: France indicts Sanofi over epilepsy drug risks; Trump talk of drug pricing in SOTU speech may backfire

By Ed Silverman

Pharmalot

If Medicare negotiated insulin prices like the VA, it could have saved billions

By Ed Silverman

Pharmalot

Pharmalittle: FDA approves peanut allergy drug; employer coalition likes House drug pricing bill

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Consumer groups and unions try again to block the AbbVie and Allergan merger

Pharmalittle: Coronavirus clinical trials are going slower than hoped; opioid lawsuit payouts may be less than expected

A city in Georgia is the latest to sue Mallinckrodt over its pricey Acthar Gel medicine

Up and down the ladder: The latest comings and goings

Pharmalittle: Generic shortages loom as coronavirus worsens; Connecticut lawmakers look to cap insulin costs

Americans with employer coverage saw growth in drug spending outpace other medical costs

As opioid crisis intensified, many family doctors found promotional pitches were very good

Pharmalittle: India struggles with coronavirus; CVS and Sanofi shake up management

Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

Pharmalittle: Big pharma isn’t stepping up to make a coronavirus vaccine; Chinese drug maker threatens Gilead patent

After a new version of a decades-old drug gets orphan status, the price suddenly skyrockets

WHO adviser says an antimicrobial fund can help a market that ‘needs to be fixed’

Pharmalittle: Trump considers executive action to cut drug prices; feds ‘not done’ with generic price-fixing probe

Pharmalittle: Two more Alzheimer’s drugs fail in studies; how Democratic candidates differ on lowering drug costs

California scolds McKesson for supplying excessive controlled substances to a children’s pharmacy

Up and down the ladder: The latest comings and goings

Pharmalittle: Novartis lottery for gene therapy begins amid tough questions; coronavirus vaccine may take a year

U.S. officials lash out at the Dutch government for moves that ‘undermine’ pharma patent rights

Pharmalittle: Buttigieg wants pharma to ‘thrive’; U.S. patent panel boosts Biogen, disappoints Gilead

Years later, raw clinical trial data tells us the extent of Avandia’s heart risks

Gilead loses its challenge to a pair of U.S. patents for an HIV prevention pill

Pharmalittle: Trump claims on drug prices are mostly false; Merck to spin off old drugs into new company

A former Taro Pharma executive is indicted in generic price-fixing probe

Pharma execs argue new Canadian regulations for setting drug prices will hurt the country

FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Pharmalittle: France indicts Sanofi over epilepsy drug risks; Trump talk of drug pricing in SOTU speech may backfire

If Medicare negotiated insulin prices like the VA, it could have saved billions

Pharmalittle: FDA approves peanut allergy drug; employer coalition likes House drug pricing bill

Up and down the ladder: The latest comings and goings